蓝丰生化
(002513)
| 流通市值：12.40亿 | | | 总市值：17.64亿 |
| 流通股本：2.64亿 | | | 总股本：3.75亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 543,942,036.72 | 1,793,141,048.95 | 1,426,638,363.1 | 849,051,865.51 |
| 营业收入 | 543,942,036.72 | 1,793,141,048.95 | 1,426,638,363.1 | 849,051,865.51 |
| 二、营业总成本 | 588,744,587.62 | 2,092,857,034.64 | 1,643,457,446.3 | 996,672,441.73 |
| 营业成本 | 531,101,730.61 | 1,831,504,327.54 | 1,441,191,157.64 | 869,751,953.42 |
| 利息支出 | - | - | 11,022,554.45 | - |
| 税金及附加 | 3,925,478.27 | 15,765,339.04 | - | 3,829,630.01 |
| 销售费用 | 12,016,371.67 | 45,649,561.13 | 32,725,354.49 | 22,094,028.66 |
| 管理费用 | 16,565,934.13 | 84,677,174.31 | 65,910,801.92 | 48,355,445.72 |
| 研发费用 | 15,858,510.05 | 68,680,051.26 | 59,544,277.01 | 37,889,370.76 |
| 财务费用 | 9,276,562.89 | 46,580,581.36 | 33,063,300.79 | 14,752,013.16 |
| 其中:利息费用 | 11,168,500.04 | 59,531,574.94 | 33,046,125.53 | 18,955,416.21 |
| 其中:利息收入 | 850,679.79 | 6,970,377.5 | 4,062,079.41 | 2,810,084.98 |
| 加:投资收益 | 304,639.89 | 1,205,864.65 | 428,549.46 | 621,010.7 |
| 资产处置收益 | -113,084.78 | -359,088.68 | -358,326.75 | -261,610.47 |
| 资产减值损失(新) | -6,317,326.29 | -68,783,694.76 | -38,004,613.44 | -29,519,919.52 |
| 信用减值损失(新) | 4,061,538.26 | -52,991,345.69 | -30,567,285.49 | -29,341,371.2 |
| 其他收益 | 4,582,560.65 | 17,047,106.13 | 14,162,796.69 | 5,850,494.44 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -42,284,223.17 | -403,597,144.04 | -271,157,962.73 | -200,271,972.27 |
| 加:营业外收入 | 4,169,804.15 | 969,352.2 | 1,208,056.61 | 650,956.72 |
| 减:营业外支出 | 63,596.94 | 32,207,716.28 | 32,222,296.96 | 26,013,134.78 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -38,178,015.96 | -434,835,508.12 | -302,172,203.08 | -225,634,150.33 |
| 减:所得税费用 | -1,525,655.58 | -81,607,521.4 | -57,298,382.32 | -48,121,458.39 |
| 六、净利润 | -36,652,360.38 | -353,227,986.72 | -244,873,820.76 | -177,512,691.94 |
| 持续经营净利润 | -36,652,360.38 | -353,227,986.72 | -244,873,820.76 | -177,512,691.94 |
| 归属于母公司股东的净利润 | -22,154,823.78 | -252,500,773.62 | -185,030,513.69 | -139,369,184.81 |
| 少数股东损益 | -14,497,536.6 | -100,727,213.1 | -59,843,307.07 | -38,143,507.13 |
| (一)基本每股收益 | -0.06 | -0.68 | -0.51 | -0.39 |
| (二)稀释每股收益 | -0.06 | -0.68 | -0.51 | -0.39 |
| 八、其他综合收益 | - | -152,827.74 | 120,107.14 | 120,107.14 |
| 归属于母公司股东的其他综合收益 | - | -157,324.59 | 120,107.14 | 120,107.14 |
| 九、综合收益总额 | -36,652,360.38 | -353,380,814.46 | -244,753,713.62 | -177,392,584.8 |
| 归属于母公司股东的综合收益总额 | -22,154,823.78 | -252,658,098.21 | -184,910,406.55 | -139,249,077.67 |
| 归属于少数股东的综合收益总额 | -14,497,536.6 | -100,722,716.25 | -59,843,307.07 | -38,143,507.13 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-06 |
| 审计意见(境内) | | 标准无保留意见 | | |